Lightnews — Scholar-powered news

Roel Verhaak

@roelverhaak.bsky.social

680 followers 150 following 51 posts

Yale Dpt of Neurosurgery, cancer research, brain tumors, ecDNA, likes football, drums and karaoke.

Posts Media Videos Starter Packs

Pinned

Roel Verhaak @roelverhaak.bsky.social · Jul 16

New preprint on longitudinal treatment response signatures in IDH-mutant glioma from the GLASS Consortium www.biorxiv.org/content/10.1...

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas

Astrocytomas and oligodendrogliomas are slow-growing and treatment-sensitive IDH-mutant gliomas diagnosed at ages 30-50. Local tumor regrowth and treatment resistance is inevitable resulting in 3-10 y...

www.biorxiv.org

2 4 15

Reposted by Roel Verhaak

Michael Platten, MD @michael-platten.bsky.social · 4d

The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/...

Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.

The immunology of brain tumors

The cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment are reviewed.

www.science.org

10 21

Roel Verhaak @roelverhaak.bsky.social · 22d

Today’s lab meeting is a debate of recent Nature/Science retraction decisions: fair or not? Important lesson that not all retractions are the same, authors not always to blame.

1 6

Roel Verhaak @roelverhaak.bsky.social · Sep 8

Phenomenal work, Dan! Read it with pleasure.

1 1

Reposted by Roel Verhaak

Sarah Aitken @s-j-aitken.bsky.social · Aug 22

Almost half way to our fundraising target - and only two weeks to go!

I'll be riding the 100 mile #CloserToFreeRide to raise money to support cancer research and patient care. Please consider donating - every penny counts!

➡️ www.rideclosertofree.org/participants...

#CTFRide @ctfride.bsky.social

1 1

Reposted by Roel Verhaak

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Aug 19

Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children.
These children need MORE funding and MORE trials, not less.
They deserve better

2 15 19

Reposted by Roel Verhaak

Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · Aug 19

🔥 Hot of the press in Neuro-Oncology! 🧠 #Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
academic.oup.com/neuro-oncolo...

@eanoassociation.bsky.social @neuroonc.bsky.social

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

Abstract. Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021 the World Health Orga

academic.oup.com

2 3

Reposted by Roel Verhaak

Yale Cancer Center @yalecancer.bsky.social · Aug 12

Findings from @roelverhaak.bsky.social et al. reveal lentiviral transduction + antibiotic selection dramatically ⬇️ ecDNA+ #cancer cells, revealing both a challenge for research and a potential therapeutic clue. #ecdna
aacrjournals.org/cancerrescom...
@aacrjournals.bsky.social

Selective depletion of cancer cells with extrachromosomal DNA via lentiviral infection

Abstract. Extrachromosomal DNA (ecDNA), a major focal oncogene amplification mode found across cancer, has recently regained attention as an emerging cancer hallmark, with a pervasive presence across ...

aacrjournals.org

2 2

Roel Verhaak @roelverhaak.bsky.social · Aug 11

Happy to provide a comment on recent work by the Maciejowski lab on ecDNA inheritance www.cell.com/molecular-ce... and authors.elsevier.com/a/1lZPK3vVUP... - with Xue Jin

authors.elsevier.com

1 6

Reposted by Roel Verhaak

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Jul 31

Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org
rdcu.be/eyHcG

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas

Nature Communications - A subset of pediatric gliomas harbour alterations in fibroblast growth factor receptor (FGFR)-family proteins. Here, the authors characterise the genomic landscape of 11,635...

rdcu.be

1 1 4

Roel Verhaak @roelverhaak.bsky.social · Jul 25

I took it for a small tortoiseshell (or its California version tortoiseshell) :) in that case, lady it is.

Roel Verhaak @roelverhaak.bsky.social · Jul 25

Could be male

Roel Verhaak @roelverhaak.bsky.social · Jul 24

You might want to check the grant status in Commons.

2 1

Roel Verhaak @roelverhaak.bsky.social · Jul 24

As individual PI, that may just set you up for further targeting.

Roel Verhaak @roelverhaak.bsky.social · Jul 23

Apparently payline was adjusted to 4th percentile for the May council. Unrelated to the budget of the grant.

2 1 4

Roel Verhaak @roelverhaak.bsky.social · Jul 23

PO just confirmed that our 5th percentile R01 is not getting funded. Past NCI Payline at 4 percent. Cant believe it.

20 92 180

Reposted by Roel Verhaak

Trevor Graham @trevorgraham.bsky.social · Jul 17

Goldschmidt's hopeful monsters in cancer: single cell DNAseq shows whole genome doubling (WGD) is an ongoing and frequent mutational process in ovarian cancer. www.nature.com/articles/s41... beautiful work from @sohrabshah.bsky.social and team

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer - Nature

A single-cell sequencing study using more than 30,000 tumour genomes from human ovarian cancers shows that whole-genome doubling is an ongoing mutational process that drives tumour evolution and disru...

www.nature.com

12 31

Roel Verhaak @roelverhaak.bsky.social · Jul 16

New preprint on longitudinal treatment response signatures in IDH-mutant glioma from the GLASS Consortium www.biorxiv.org/content/10.1...

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas

www.biorxiv.org

2 4 15

Roel Verhaak @roelverhaak.bsky.social · Jul 15

Fabulous idea with some telling results!

Reposted by Roel Verhaak

Sarah Aitken @s-j-aitken.bsky.social · Jun 27

Together with friends and colleagues from #CMCO @yalecancer.bsky.social, @yalepathology.bsky.social, and further afield, we are the #CycloPaths

Closer to Free Ride
🚲06 September 2025
💪100 miles
#CTFRide

Join our team, spread the word, sponsor us if you can www.rideclosertofree.org/participants...

A fundraising page for Sarah Aitken

Join the Closer to Free Ride on Saturday, September 6th. Register or donate at RideCloserToFree.org.

www.rideclosertofree.org

1 1 8

Roel Verhaak @roelverhaak.bsky.social · Jun 27

After three days of engaged discussions, we wrapped up the 2025 Mark Foundation on Genomic Instability. What a fun event with amazing participants.

1 4

Reposted by Roel Verhaak

The Mark Foundation for Cancer Research @themarkfdn.bsky.social · Jun 24

It's 102°F/39°C in New Haven—but 30 international experts have braved the heatwave to join us at @yaleschoolofmed.bsky.social for a 3-day workshop on chromosomal instability in cancer. Thank you to our workshop organizers @roelverhaak.bsky.social, Florian Markowetz, & Aurelie Ernst!

1 4

Roel Verhaak @roelverhaak.bsky.social · Jun 24

Excited to host nearly 30 international experts for the @themarkfdn.bsky.social workshop on genomic instability in cancer at @yaleschoolofmed.bsky.social today! This area of research is ready for the next breakthrough. @yalecancer.bsky.social

1 5

Reposted by Roel Verhaak

Nicolas Robine @nicorobine.bsky.social · Jun 18

Resolving spatial subclonal genomic heterogeneity of loss of heterozygosity and extrachromosomal DNA in gliomas
www.nature.com/articles/s41...

Resolving spatial subclonal genomic heterogeneity of loss of heterozygosity and extrachromosomal DNA in gliomas - Nature Communications

Currently, there is limited knowledge about the spatial heterogeneity of glioma-driving molecular events. Here, the authors employ a multiomics approach to characterize the spatial transcriptomic hete...

www.nature.com

1 1

Reposted by Roel Verhaak

Yale Cancer Center @yalecancer.bsky.social · May 27

[email protected]: “We’re recognizing that we need a paradigm shift – that we need to approach the disease [#braincancer] differently than we have so far.”
yalecancercenter.org/news-article...
@theaacr.bsky.social #NCRM25 #unitedbycancerresearch #btsm

'Paradigm Shift' in Brain Cancer Research Needed, Says Yale Professor

Researchers need to find solutions differently than in the past to break through with treatments for aggressive brain cancers.

yalecancercenter.org

1 5

Reposted by Roel Verhaak

Kadir Akdemir @kcakdemir.bsky.social · May 22

Excited to share our latest manuscript www.biorxiv.org/content/10.1...
This was a great collaboration with Drs. Huse, Lang, @jesserdixon.bsky.social

1 6 15